Codexis Reports Q3 2026 Revenue Growth and Narrowing Net Loss
Codexis (CDXS) reported strong third-quarter 2026 financial results, characterized by a significant revenue increase to $19.3 million, up from $8.6 million in the prior-year period. This growth was primarily driven by higher product sales and the launch of new high-margin customer products. The company also successfully narrowed its net loss to $8.1 million, an improvement over the $19.6 million loss reported in Q3 2025. Technologically, Codexis achieved a major milestone with its ECO Synthesis platform by reaching 100-gram production scale and reducing cycle times by 40%. The company's biocatalysis business is seeing renewed momentum, supported by three drug approvals this year. With $72.7 million in cash and short-term investments, management projects a cash runway extending through the end of 2028.
Tickers: $CDXS
Topics: Financial Guidance Gross Margin Improvement Net Loss Reduction Revenue Growth